Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish
inflammation in patients with sarcoidosis. Subjects with active sarcoidosis will first
undergo bronchoscopy with bronchoalveolar lavage to recover lung immune cells for baseline
analysis. They will then receive the drug maraviroc for 6 weeks duration. They will then
undergo a repeat bronchoscopy with bronchoalveolar lavage to recover lung immune cells for
analysis following maraviroc treatment.